UNSPSC 51413403: Dihydroergocristine

This classification denotes a dopamine agonist and alpha-adrenergic blocking agent with the molecular formula C35H41N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05D48LUM4Z, chemically known as ergocristine, dihydro- but generally known as dihydroergocristine, which bears US NIH Compound Identifier 3065. European Medicines Agency schedules Dihydroergocristine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13586MIG.

UNSPSC 51413403 Dihydroergocristine, a Commodity code, covers pharmaceutical active ingredients and finished medications procured by state and local health systems, emergency services, and public health programs. State and local buyers under this code solicit both individual medication line items for emergency medical services and broad-based pharmaceutical supply agreements serving multiple jurisdictions and state agencies. The issuing bodies include municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances administering agreements on behalf of participating state and local government facilities.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026, estimated contract value $40,000) supplying four specific medication line items to Tampa Fire Rescue, with a one-year term plus renewal options and a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. Cooperative purchasing vehicles and multistate agreements characterize the higher-volume procurement landscape, while direct municipal procurement for emergency services remains an active channel.